While the maintenance of an Outperform rating indicates continued analyst confidence in Corvus Pharma's potential, the reduction in the price target could suggest a tempered outlook on the stock's short-term price performance. This adjustment reflects a nuanced view on the company's valuation, potentially due to updated financial analysis or market conditions. Investors might see this as a mixed signal, balancing positive growth expectations against a slightly more conservative valuation estimate.